The Impact of Long COVID-19 on Mental Health: Observational 6-Month Follow-Up Study.
COVID-19
PASC
SARS-CoV-2
anxiety
corona
depression
post-traumatic stress disorder
Journal
JMIR mental health
ISSN: 2368-7959
Titre abrégé: JMIR Ment Health
Pays: Canada
ID NLM: 101658926
Informations de publication
Date de publication:
24 Feb 2022
24 Feb 2022
Historique:
received:
20
09
2021
accepted:
05
01
2022
revised:
28
11
2021
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
2
2022
Statut:
epublish
Résumé
The psychological impact of COVID-19 can be substantial. However, knowledge about long-term psychological outcomes in patients with COVID-19 is scarce. In this longitudinal, observational study, we aimed to reveal symptoms of posttraumatic stress disorder (PTSD) and symptoms of anxiety and depression up to 6 months after the onset of COVID-19-related symptoms in patients with confirmed COVID-19 and persistent complaints. To demonstrate the impact in nonhospitalized patients, we further aimed to compare these outcomes between nonhospitalized and hospitalized patients. Demographics, symptoms of PTSD (Trauma Screening Questionnaire [TSQ] ≥6 points) and symptoms of anxiety and depression (Hospital Anxiety and Depression Scale [HADS] ≥8 points) were assessed at 3 and 6 months after the onset of COVID-19-related symptoms in members of online long COVID-19 peer support groups. Data from 239 patients with confirmed COVID-19 (198/239, 82.8% female; median age: 50 [IQR 39-56] years) were analyzed. At the 3-month follow-up, 37.2% (89/239) of the patients had symptoms of PTSD, 35.6% (85/239) had symptoms of anxiety, and 46.9% (112/239) had symptoms of depression, which remained high at the 6-month follow-up (64/239, 26.8%, P=.001; 83/239, 34.7%, P=.90; 97/239, 40.6%, P=.08, respectively; versus the 3-month follow-up). TSQ scores and HADS anxiety and depression scores were strongly correlated at the 3- and 6-month follow-ups (r=0.63-0.71, P<.001). Symptoms of PTSD, anxiety, and depression were comparable between hospitalized (n=62) and nonhospitalized (n=177) patients. A substantial percentage of patients with confirmed COVID-19 and persistent complaints reported symptoms of PTSD, anxiety, or depression 3 and 6 months after the onset of COVID-19-related symptoms. The prevalence rates of symptoms of PTSD, anxiety, and depression were comparable between hospitalized and nonhospitalized patients and merely improved over time. Health care professionals need to be aware of these psychological complications and intervene on time in post-COVID-19 patients with persistent complaints. Netherlands Trial Register NTR8705; https://www.trialregister.nl/trial/8705.
Sections du résumé
BACKGROUND
BACKGROUND
The psychological impact of COVID-19 can be substantial. However, knowledge about long-term psychological outcomes in patients with COVID-19 is scarce.
OBJECTIVE
OBJECTIVE
In this longitudinal, observational study, we aimed to reveal symptoms of posttraumatic stress disorder (PTSD) and symptoms of anxiety and depression up to 6 months after the onset of COVID-19-related symptoms in patients with confirmed COVID-19 and persistent complaints. To demonstrate the impact in nonhospitalized patients, we further aimed to compare these outcomes between nonhospitalized and hospitalized patients.
METHODS
METHODS
Demographics, symptoms of PTSD (Trauma Screening Questionnaire [TSQ] ≥6 points) and symptoms of anxiety and depression (Hospital Anxiety and Depression Scale [HADS] ≥8 points) were assessed at 3 and 6 months after the onset of COVID-19-related symptoms in members of online long COVID-19 peer support groups.
RESULTS
RESULTS
Data from 239 patients with confirmed COVID-19 (198/239, 82.8% female; median age: 50 [IQR 39-56] years) were analyzed. At the 3-month follow-up, 37.2% (89/239) of the patients had symptoms of PTSD, 35.6% (85/239) had symptoms of anxiety, and 46.9% (112/239) had symptoms of depression, which remained high at the 6-month follow-up (64/239, 26.8%, P=.001; 83/239, 34.7%, P=.90; 97/239, 40.6%, P=.08, respectively; versus the 3-month follow-up). TSQ scores and HADS anxiety and depression scores were strongly correlated at the 3- and 6-month follow-ups (r=0.63-0.71, P<.001). Symptoms of PTSD, anxiety, and depression were comparable between hospitalized (n=62) and nonhospitalized (n=177) patients.
CONCLUSIONS
CONCLUSIONS
A substantial percentage of patients with confirmed COVID-19 and persistent complaints reported symptoms of PTSD, anxiety, or depression 3 and 6 months after the onset of COVID-19-related symptoms. The prevalence rates of symptoms of PTSD, anxiety, and depression were comparable between hospitalized and nonhospitalized patients and merely improved over time. Health care professionals need to be aware of these psychological complications and intervene on time in post-COVID-19 patients with persistent complaints.
TRIAL REGISTRATION
BACKGROUND
Netherlands Trial Register NTR8705; https://www.trialregister.nl/trial/8705.
Identifiants
pubmed: 35200155
pii: v9i2e33704
doi: 10.2196/33704
pmc: PMC8914795
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e33704Informations de copyright
©Sarah Houben-Wilke, Yvonne MJ Goërtz, Jeannet M Delbressine, Anouk W Vaes, Roy Meys, Felipe VC Machado, Maarten van Herck, Chris Burtin, Rein Posthuma, Frits ME Franssen, Herman Vijlbrief, Yvonne Spies, Alex J van 't Hul, Martijn A Spruit, Daisy JA Janssen. Originally published in JMIR Mental Health (https://mental.jmir.org), 24.02.2022.
Références
EClinicalMedicine. 2021 Feb;32:100731
pubmed: 33532720
Front Psychiatry. 2020 Nov 20;11:586355
pubmed: 33329130
World Psychiatry. 2010 Feb;9(1):3-10
pubmed: 20148146
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Gen Intern Med. 2021 Jun;36(6):1702-1707
pubmed: 33782888
Community Ment Health J. 2010 Feb;46(1):20-5
pubmed: 19396545
Ann N Y Acad Sci. 2021 Feb;1486(1):90-111
pubmed: 33009668
Psychiatry Res. 2020 Sep;291:113138
pubmed: 32562931
Ann Am Thorac Soc. 2022 Apr;19(4):551-561
pubmed: 34582728
Clinics (Sao Paulo). 2020;75:e1921
pubmed: 32401964
Aust J Gen Pract. 2020 Dec;49(12):778-783
pubmed: 33254205
Clin Microbiol Infect. 2020 Nov;26(11):1448-1449
pubmed: 32712242
Brain Behav Immun. 2020 Oct;89:531-542
pubmed: 32485289
Indian J Psychiatry. 2020 Sep;62(Suppl 3):S365-S372
pubmed: 33227076
J Patient Exp. 2021 Mar 8;8:2374373521997222
pubmed: 34179387
ERJ Open Res. 2021 May 24;7(2):
pubmed: 34041295
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Crit Care. 2019 Jun 11;23(1):213
pubmed: 31186070
J Clin Med. 2020 Sep 12;9(9):
pubmed: 32932582
J Clin Med. 2020 Dec 09;9(12):
pubmed: 33317214
Psychol Med. 2020 Nov 27;:1-2
pubmed: 33243309
BMC Psychiatry. 2005 Dec 14;5:46
pubmed: 16351733
Health Qual Life Outcomes. 2021 Feb 3;19(1):40
pubmed: 33536042
Cochrane Database Syst Rev. 2018 Dec 14;12:CD011710
pubmed: 30550643
Crit Care. 2019 Feb 8;23(1):39
pubmed: 30736830
JAMA Psychiatry. 2021 May 1;78(5):567-569
pubmed: 33599709
Aust J Gen Pract. 2020 Dec;49(12):785-789
pubmed: 33254204
Glob Health Res Policy. 2020 Jun 5;5:29
pubmed: 32514428
Healthcare (Basel). 2020 Sep 30;8(4):
pubmed: 33008081
Medicina (Kaunas). 2021 May 12;57(5):
pubmed: 34065845
Psychiatry Res. 2020 Sep;291:113267
pubmed: 32623266
Aging Ment Health. 2021 Jul;25(7):1289-1296
pubmed: 33291948
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34580069
Lancet Psychiatry. 2020 Jul;7(7):611-627
pubmed: 32437679
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2474-2480.e1
pubmed: 32679348
Brain Behav Immun. 2020 Oct;89:594-600
pubmed: 32738287
Front Psychol. 2020 Sep 09;11:2201
pubmed: 33013572
J Korean Med Sci. 2021 Jan 18;36(3):e33
pubmed: 33463098
Br J Psychiatry. 2002 Aug;181:158-62
pubmed: 12151288
Epidemiol Health. 2020;42:e2020038
pubmed: 32512661
Int J Environ Res Public Health. 2021 Jun 03;18(11):
pubmed: 34205086
Panminerva Med. 2021 Jun 01;:
pubmed: 34060280
BMC Health Serv Res. 2020 Dec 20;20(1):1144
pubmed: 33342437
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Eur Respir J. 2021 Jun 24;57(6):
pubmed: 33795319
Asia Pac Psychiatry. 2021 Jun;13(2):e12443
pubmed: 33135397